Scholars Central

CommentaryPublished 23 Mar 2022

Prognosis of Heart Failure and Sympathetic Nerve Activity

Authors: Shinya Minatoguchi

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The prognosis of heart failure is poor and plasma noradrenaline level is a good predictor of the survival rate of heart failure patients. Sympathetic nerve activity is augmented in patients with heart failure as evidenced by a higher noradrenaline release rate from the sympathetic nerve endings. Drugs for heart failure such as β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid antagonists, ivabradine, Angiotensin Receptor-Neprilysin Inhibitor (ARNI), and Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors have clinical evidences for improving prognosis of heart failure in large randomized-controlled clinical trials. Interestingly, the same characteristics in common of these drugs is to reduce sympathetic nerve activity. In addition, cardiac rehabilitation which causes a better prognosis of heart failure reduces the sympathetic nerve activity. In conclusion, to optimize excessively augmented sympathetic nerve activity may be related to an improvement of prognosis of heart failure.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Physical Medicine & Rehabilitation
  • SubjectPhysical Therapy & Rehabilitation
  • BylineArticles whose byline prints “Shinya Minatoguchi”